Cancer Research SABCS Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finch, R. A.
Right arrow Articles by Sartorelli, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finch, R. A.
Right arrow Articles by Sartorelli, A. C.
[Cancer Research 61, 3033-3038, April 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): A Novel Sulfonylhydrazine Prodrug with Broad-Spectrum Antineoplastic Activity1

Rick A. Finch, Krishnamurthy Shyam, Philip G. Penketh and Alan C. Sartorelli2

Department of Pharmacology and Developmental Therapeutics Program, Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520

Our laboratory has synthesized and evaluated the anticancer activity of a number of sulfonylhydrazine DNA modifying agents. As a class, these compounds possess broad spectrum antitumor activity, demonstrating significant activity against a variety of experimental murine tumors, including the P388 and L1210 leukemias, B16 melanoma, M109 lung carcinoma, and M5076 reticulum cell sarcoma, as well as against the human LX-1 lung carcinoma xenograft. The current report describes the activity of a more recently synthesized member of this class, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M). 101M was active in mice against the i.p. implanted L1210 leukemia over a wide range of doses and produced long-term survivors when administered as a single i.p. bolus of 10, 20, 40, 60, or 80 mg/kg, demonstrating a wider margin of safety than the nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Curative therapy was achieved with doses of 101M that did not produce depression of the bone marrow. 101M was also highly effective against the L1210 leukemia when administered by the oral route. The ability of 101M to penetrate the blood-brain barrier and eradicate leukemia cells in the brain was remarkable (>6 log kill). This agent was also curative against L1210 variants resistant to cyclophosphamide, BCNU, or melphalan. Mice implanted with the murine C26 colon carcinoma were also cured by two injections of 10 or 20 mg/kg of 101M. Administration of 101M by two different well-tolerated regimens caused complete regression of established human glioblastoma U251 xenografts in 100% of treated mice, and significant responses were also obtained with 101M against advanced murine M109 lung carcinomas in mice. The broad spectrum of anticancer activity of the sulfonylhydrazine prodrug 101M coupled with the wide range of therapeutic safety exhibited by this agent, makes 101M particularly attractive for further development and clinical evaluation.




This article has been cited by other articles:


Home page
 BloodHome page
F. Giles, N. Vey, D. DeAngelo, K. Seiter, W. Stock, R. Stuart, D. Boskovic, A. Pigneux, M. Tallman, J. Brandwein, et al.
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
Blood, November 5, 2009; 114(19): 4027 - 4033.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A.-E. F. Nassar, I. King, B. L. Paris, L. Haupt, F. Ndikum-Moffor, R. Campbell, E. Usuki, J. Skibbe, D. Brobst, B. W. Ogilvie, et al.
An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes
Drug Metab. Dispos., September 1, 2009; 37(9): 1922 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Laubach and A. V. Rao
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Oncologist, October 1, 2008; 13(10): 1097 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Gururangan, C. D. Turner, C. F. Stewart, M. O'Shaughnessy, M. Kocak, T. Y. Poussaint, P. C. Phillips, S. Goldman, R. Packer, I. F. Pollack, et al.
Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study
Clin. Cancer Res., February 15, 2008; 14(4): 1124 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. A. Badruddoja, S. T. Keir, I. King, J. Zeidner, J. J. Vredenburgh, L. H. Muhlbaier, D. D. Bigner, and H. S. Friedman
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice
Neuro-oncol, July 1, 2007; 9(3): 240 - 244.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al.
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Ishiguro, H. A. Seow, P. G. Penketh, K. Shyam, and A. C. Sartorelli
Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.
Mol. Cancer Ther., April 1, 2006; 5(4): 969 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Ishiguro, K. Shyam, P. G. Penketh, and A. C. Sartorelli
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine
Mol. Cancer Ther., November 1, 2005; 4(11): 1755 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, S. Verstovsek, D. Thomas, S. Gerson, J. Cortes, S. Faderl, A. Ferrajoli, F. Ravandi, S. Kornblau, G. Garcia-Manero, et al.
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7817 - 7824.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. A. Seow, P. G. Penketh, K. Shyam, S. Rockwell, and A. C. Sartorelli

PNAS, June 28, 2005; 102(26): 9282 - 9287.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran, C. Koller, et al.
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Clin. Cancer Res., May 1, 2004; 10(9): 2908 - 2917.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.